TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System

TNF-alpha inhibitors have revolutionized the therapeutic care in chronic inflammatory diseases. Several biosimilar products were commercialized at their patent expiry, substantially decreasing the cost of treatment. This longitudinal descriptive study aimed at assessing infliximab, etanercept and ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Jourdain, Hugo, Hoisnard, Léa, Sbidian, Emilie, Zureik, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666557/
https://www.ncbi.nlm.nih.gov/pubmed/36380105
http://dx.doi.org/10.1038/s41598-022-24050-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666557/
https://www.ncbi.nlm.nih.gov/pubmed/36380105
http://dx.doi.org/10.1038/s41598-022-24050-7

Ejemplares similares